Clinical trial NCT01593072: A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Ebola Hemorrhagic Fever
Keywords: Multiple Ascending Dose (MAD)
Ebola Virus
Post Exposure Prophylaxis
EHF
Lead sponsor: Sarepta Therapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: United States Department of Defense
First posted: 2012-05-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).

Detailed description: The purpose of this study is to evaluate the safety and tolerability of 14 once daily intravenous (IV) infusions of ascending doses of AVI 7537 compared to matched placebo in healthy male and female subjects.

To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects

Eligibility criteria: Inclusion Criteria:

A subject must meet all of the following criteria to be eligible for this study.

1. Man or woman 18 to 50 years of age, inclusive, at the time of screening.
2. Body mass index 18 kg/m2 to 35 kg/m2, inclusive, at the time of screening and Check-in (Day -1).
3. Good general health (no chronic health conditions) as determined by the Investigator.
4. Female subjects must be of non-childbearing potential (e.g., be confirmed post-menopausal or have undergone surgical sterilization) or must, in conjunction with their sexual partner(s), use 2 forms of medically acceptable contraception (e.g., oral contraception in conjunction with a male condom) during the screening period and for the entire duration of the study including the 28-day post last dose follow-up.
5. Male subjects must either be sterile or agree to use, for the entire duration of the study including the 28 day post last dose follow-up, a male condom and the female sexual partner must also use a medically acceptable form of birth control (e.g. oral contraceptives).
6. Male subjects must agree to not donate sperm for at least 30 days after the last infusion of study medication.
7. Able to understand the requirements of the study, to provide written informed consent (as evidenced by signature on an informed consent document that is approved by an Institutional Review Board \[IRB\]), and agreeable to abiding by the study restrictions.

Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from this study.

1. Pregnancy or breastfeeding.
2. A positive urine or blood screen for drugs of abuse, including alcohol.
3. Use of any tobacco- or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to Check-in (Day -1).
4. A positive cotinine test indicating recent nicotine use.
5. Donated blood within 90 days or plasma within 30 days of first dose on Day 1.
6. Active substance abuse or any medical or psychiatric condition that could jeopardize the subject's safety or the subject's ability to comply with the protocol.
7. Use of any medications apart from vitamins, acetaminophen, or hormonal contraception within 14 days of first dose on Day 1. Subjects with mild seasonal allergies may use antihistamines at the discretion of the Investigator after approval by the Sponsor Medical Monitor.
8. Participation in any interventional clinical trial within 45 days of first dose on Day 1 (i.e., received any other investigational drug).
9. Recipient of an organ transplant (solid or hematopoietic).
10. Prolonged QTcF interval \> 440 ms for males or \> 460 ms for females using the average of the triplicate electrocardiograms (ECGs) collected during screening, on Day -1, or just prior to dosing on Day 1.
11. Other clinically significant ECG abnormality, as determined by the Investigator.
12. Any clinically significant abnormal hematology, chemistry, coagulation, or urinalysis value, as determined by the Investigator.
13. Glomerular filtration rate (GFR) of \< 80 mL/min, based on the Modification of Diet in Renal Disease equation.
14. Urine-albumin-to-creatinine ratio (UACR) \> 30 mg/g.
15. Positive test for human immunodeficiency virus (HIV-1 serology) or known HIV infection.
16. Positive result for hepatitis B surface antigen (HBsAg) or for hepatitis C virus (HCV) antibody.
17. Use of alcohol-containing foods or beverages within 72 hours prior to Check-in on Day -1.
18. Use of caffeine-containing foods or beverages within 24 hours prior to Check-in on Day -1.
19. Febrile illness or significant infection within 48 hours before administration of the first dose of study drug on Day 1.

Note: Inclusion of each subject will be reviewed with a member of AVI BioPharma Clinical Personnel prior to enrollment in the trial. Written approval from a member of AVI BioPharma Clinical Personnel is required prior to randomization.

Primary outcomes:
measure: The outcome measures are Serial PK Day 1 over 24 hrs(pre-dose,10 min post,30 min post, 1hr 1.5,2,4,6, 8, 12,16,24,28,32,36, and 48 hrs post-dose), daily through level and on Day 14 (last day of dosing) serial PK until 48 hrs post last dose.
timeFrame: 2 weeks
Secondary outcomes:
measure: To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects,
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Quintiles Phase I Services
state: Kansas
Study officials:
affiliation: Sarepta Therapeutics, Inc.
name: Alison Heald, MD
role: PRINCIPAL_INVESTIGATOR
References: